Evidence map›Paper›PMID 25923540›Full record

ArticlePloS one2015

Boceprevir or Telaprevir Based Triple Therapy against Chronic Hepatitis C in HIV Coinfection: Real-Life Safety and Efficacy.

Karin Neukam, Daniela I Munteanu, Antonio Rivero-Juárez, Thomas Lutz, Jan Fehr, Mattias Mandorfer, Sanjay Bhagani, Luis F López-Cortés, Annette Haberl, Marcel Stoeckle and 9 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in PloS one, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Treatment of hepatitis C in special populations.Journal of gastroenterology · 2018
    Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors.

Karin NeukamUnit of Infectious Diseases and Microbiology, Valme University Hospital and Seville Institute of Biomedicine (IBiS), Seville, Spain; RIS-HEP07 Study Group of the Spanish AIDS Research Network.
Daniela I MunteanuDepartment of Medicine I, Bonn University Hospital, Bonn-Venusberg, Germany; Matei Bals National Institute of Infectious Diseases, Bucharest, Romania.
Antonio Rivero-JuárezRIS-HEP07 Study Group of the Spanish AIDS Research Network; Unit of Infectious Diseases, Reina Sofía University Hospital, Maimónides Institute of Biomedical Investigation of Cordoba (IMIBIC), Cordoba, Spain.
Thomas LutzInfektiologikum Frankfurt, Frankfurt/Main, Germany.
Jan FehrDivision of Infectious Diseases & Hospital Epidemiology, University Hospital Zurich, University of Zurich, Zurich, Switzerland.
Mattias MandorferDivision of Gastroenterology and Hepatology, Department of Internal Medicine III, Medical University of Vienna and Vienna HIV & Liver Study Group, Vienna, Austria.
Sanjay BhaganiDepartment of Infectious Diseases/HIV Medicine, Royal Free London NHS Foundation Trust, London, United Kingdom.
Luis F López-CortésRIS-HEP07 Study Group of the Spanish AIDS Research Network; Infectious Diseases, Microbiology and Preventive Medicine, Virgen del Rocío University Hospital and Seville Institute of Biomedicine (IBiS), Seville, Spain.
Annette HaberlDepartment of Medicine II, Frankfurt University Hospital, Frankfurt/Main, Germany.
Marcel StoeckleDivision of Infectious Diseases & Hospital Epidemiology, University Hospital Basel, Basel, Switzerland.
Manuel MárquezRIS-HEP07 Study Group of the Spanish AIDS Research Network; Unit of Infectious Diseases, Virgen de la Victoria University Hospital, Malaga, Spain.
Stefan ScholtenPraxis Hohenstaufenring, Cologne, Germany.
Ignacio de Los Santos-GilRIS-HEP07 Study Group of the Spanish AIDS Research Network; Infectious Diseases Unit, La Princesa University Hospital, Madrid, Spain.
Stefan MaussCenter for HIV and Hepatogastroenterology, Dusseldorf, Germany.
Antonio RiveroRIS-HEP07 Study Group of the Spanish AIDS Research Network; Unit of Infectious Diseases, Reina Sofía University Hospital, Maimónides Institute of Biomedical Investigation of Cordoba (IMIBIC), Cordoba, Spain.
Antonio ColladoInfectious Diseases Unit, Torrecardenas University Hospital, Almeria, Spain.
Marcial DelgadoUnit of Infectious Diseases, Carlos Haya Regional University Hospital, Malaga, Spain.
Juergen K RockstrohDepartment of Medicine I, Bonn University Hospital, Bonn-Venusberg, Germany.
Juan A PinedaUnit of Infectious Diseases and Microbiology, Valme University Hospital and Seville Institute of Biomedicine (IBiS), Seville, Spain; RIS-HEP07 Study Group of the Spanish AIDS Research Network.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND AND

aimsClinical trials of therapy against chronic hepatitis C virus (HCV) infection including boceprevir (BOC) or telaprevir (TVR) plus pegylated interferon and ribavirin (PR) have reported considerably higher response rates than those achieved with PR alone. This study sought to evaluate the efficacy and safety of triple therapy including BOC or TVR in combination with PR in HIV/HCV-coinfected patients under real-life conditions.

methodsIn a multicentre study conducted in 24 sites throughout five European countries, all HIV/HCV-coinfected patients who initiated a combination of BOC or TVR plus PR and who had at least 60 weeks of follow-up, were analyzed. Sustained virologic response 12 weeks after the scheduled end of therapy date (SVR12) and the rate of discontinuations due to adverse events (AE) were evaluated.

resultsOf the 159 subjects included, 127 (79.9%) were male, 45 (34.4%) were treatment-naïve for PR and 60 (45.4%) showed cirrhosis. SVR12 was observed in 31/46 (67.4%) patients treated with BOC and 69/113 (61.1%) patients treated with TVR. Overall discontinuations due to AE rates were 8.7% for BOC and 8% for TVR. Grade 3 or 4 hematological abnormalities were frequently observed; anemia 7%, thrombocytopenia 17.2% and neutropenia 16.4%.

conclusionThe efficacy and safety of triple therapy including BOC or TVR plus PR under real-life conditions of use in the HIV/HCV-coinfected population was similar to what is observed in clinical trials. Hematological side effects are frequent but manageable.

Indexed as

AdultCoinfectionDrug-Related Side Effects and Adverse ReactionsEuropeFemaleHepacivirusHepatitis C, ChronicHIVHIV InfectionsHumansMaleMiddle AgedOligopeptidesProlineRibavirinTreatment OutcomeN-(3-amino-1-(cyclobutylmethyl)-2,3-dioxopropyl)-3-(2-((((1,1-dimethylethyl)amino)carbonyl)amino)-3,3-dimethyl-1-oxobutyl)-6,6-dimethyl-3-azabicyclo(3.1.0)hexan-2-carboxamideOligopeptidesProlineRibavirintelaprevir

Identifiers

PMID25923540
PMCPMC4414348

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.